Moderna amends bylaws for federal forum exclusivity; stockholders re-elect directors

On May 6, 2026 , the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated By-Laws (the “By-Law Amendment”), effective immediately, to designate the federal district courts of the United States as the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, unless the Company consents in writing to the selection of an alternative forum.

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, with the votes cast as follows: Votes For Votes Against Abstain 298,823,277 3,406,479 285,923

By the vote reflected below, the Company’s stockholders elected each of the following individuals to serve as a Class II director for a three-year term expiring at the Company’s 2029 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified, or such director’s earlier death, resignation or removal: Votes For Votes Against Abstain Broker Non-Votes Sandra Horning, M.D. 210,914,932 49,357,015 331,868 41,911,864 Abbas Hussain 256,398,374 4,015,044 190,397 41,911,864

The results of the stockholders’ vote to hold an advisory vote to determine the frequency of future stockholder advisory votes on the compensation paid to the Company’s named executive officers were as follows: 1 year 2 years 3 years Abstain 259,590,666 113,043 618,688 281,418

The Company’s stockholders approved, on an advisory basis, the compensation of the named executive officers. The result of the stockholders’ vote with respect to the approval of the compensation of the named executive officers was as follows: Votes For Votes Against Abstain 169,401,841 90,761,924 440,050 There were 41,911,864 broker non-votes on the proposal.